Elsevier

The Lancet

Volume 345, Issue 8965, 24 June 1995, Pages 1604-1606
The Lancet

Avoiding unsuspected respiratory side-effects of topical timolol with cardioselective or sympathomimetic agents

https://doi.org/10.1016/S0140-6736(95)90116-7Get rights and content

Abstract

Topical timolol given for the treatment or chronic simple glaucoma may cause unrecognised bronchospasm among elderly people. We recruited 80 patients aged over 60 years, who were without a history of airways disease and already used timolol, into a randomised crossover study comparing the effects on spirometry and exercise tolerance of changing to betaxolol or dipivefrine therapy. Results showed an increase of 13% and 8% in mean peak flow rate and forced expiratory volume in 1 s (FEV1), respectively, when using betaxolol; and of 14% and 11% when using dipivefrine. There was also improved exercise tolerance with both agents. More than a quarter of the patients showed at least a 15% improvement in FEV1 when changed from timolol. Analysis of enrolment symptoms and response to nebulised salbutamol failed to produce a method of identifying these patients. Timolol may impair respiratory function and exercise tolerance of elderly patients even if they have no history of reversible airways disease.

References (22)

  • Ms Passo et al.

    Plasma timolol in glaucoma patients

    Ophthalmology

    (1984)
  • Dk Banerjee et al.

    Underdiagnosis of asthma in the elderly

    Br J Dis Chest

    (1987)
  • C. Migdal et al.

    Long-term functional outcome after early surgery compared with laser and medicine in open-angle glaucoma

    Ophthalmology

    (1994)
  • Jm Gibson et al.

    A study of the prevalence of eye disease in the elderly in an English community

    Trans Ophthalmol Soc UK

    (1985)
  • Sh Campbell et al.

    Double-masked three-period crossover investigation of timolol in control of raised intraocular pressure

    Eye

    (1993)
  • Rb Schoene et al.

    Timolol induced bronchospasm in asthmatic bronchitis

    JAMA

    (1981)
  • P. Diggory et al.

    Improved lung function tests on changing from topical timolol. Non-selective beta-blockade impairs the lung function tests of elderly people

    Eye

    (1993)
  • Ar Berrospi et al.

    Betaxolol. A new beta-adrinergic blocking agent for treatment of glaucoma

    Arch Ophthalmol

    (1982)
  • Ma Kass et al.

    Dipivefrin and epinephrine treatment of elevated intraocular pressure

    Arch Ophthalmol

    (1979)
  • HM. Hodkinson

    Mental impairment in the elderly

    J R Col Physicians Lond

    (1973)
There are more references available in the full text version of this article.

Cited by (92)

  • Ophthalmic administration of a 10-fold-lower dose of conventional nanoliposome formulations caused levels of intraocular pressure similar to those induced by marketed eye drops

    2018, European Journal of Pharmaceutical Sciences
    Citation Excerpt :

    The effectiveness of the marketed ocular TM products is restricted by extremely low bioavailability of the drug. Ophthalmic TM delivery has certain restrictions due to the structure of the eyeball: some instilled amount is absorbed by the conjunctiva, passing into the systemic circulation, without exerting its therapeutic effect; also, the frequent instillation can generate an excessive loss of drug through nasolacrimal drainage causing respiratory and cardiovascular side effects (Diggory et al., 1995). In addition, the mucin present in the tear film has a protective effect preventing tear evaporation due to the formation of a hydrophilic gel layer, but also this glycoprotein limits the penetration of the drug.

  • Dipivefrine

    2007, xPharm: The Comprehensive Pharmacology Reference
View all citing articles on Scopus
View full text